8-K: Phathom Pharma Reports Strong Q2 2026 Results, Boosts Guidance

Phathom Pharmaceuticals announced record Q2 2026 net revenues of $74.3 million, an 88% increase year-over-year, alongside a significant reduction in operating expenses and achievement of operating profitability excluding stock-based compensation.

Summary

• Phathom Pharmaceuticals reported record net revenues of $74.3 million for the second quarter of 2026, an 88% increase compared to the same period in 2025 and a 27% increase from Q1 2026.
• Operating expenses for Q2 2026 were $63.1 million, a 33% decrease from Q2 2025, driven by reduced commercial promotional spending and personnel costs.
• The company achieved operating profitability, excluding stock-based compensation, for the first time.
• VOQUEZNA prescriptions filled to date reached approximately 1.7 million, with 325,000 prescriptions filled in Q2 2026, an 88% increase year-over-year.
• Phathom is initiating a Phase 3 clinical trial for VOQUEZNA's as-needed dosing in Non-Erosive GERD (NERD), with first enrollment expected in Q4 2026.
• Enrollment for the Phase 2 trial in Eosinophilic Esophagitis (EoE) was completed in June 2026, with topline results expected in Q4 2026.
• Full-year 2026 financial guidance for net revenue has been updated to $310-$325 million, and non-GAAP operating expenses (excluding stock-based compensation) are projected between $235-$245 million.
• As of June 30, 2026, cash and cash equivalents were $182.5 million, and the company believes current cash and anticipated future cash flow are sufficient to fund operations and meet debt obligations without additional financing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, significant cost reductions, and progress in the clinical pipeline, although a slight downward revision in full-year revenue guidance and a continued net loss prevent a higher score.

Positives

• Record Q2 2026 net revenues of $74.3 million, up 88% year-over-year.
• Significant reduction in operating expenses by 33% year-over-year to $63.1 million.
• Achieved operating profitability (excluding stock-based compensation) for the first time.
• Strong prescription growth for VOQUEZNA, with 325,000 filled in Q2 2026, up 88% year-over-year.
• Updated full-year 2026 net revenue guidance increased to $310-$325 million.
• Sufficient cash reserves of $182.5 million and belief in ability to fund operations without additional financing.
• Positive progress in clinical pipeline with initiation of Phase 3 for as-needed VOQUEZNA and completion of EoE Phase 2 enrollment.

Negatives

• Net loss for Q2 2026 was $17.6 million, although significantly reduced from $75.8 million in Q2 2025.
• Non-GAAP adjusted net loss for Q2 2026 was $0.1 million, indicating a slight loss on a non-GAAP basis.
• Full-year 2026 net revenue guidance was revised downwards from the previous range of $320-$345 million to $310-$325 million.

Risks

• Potential for market acceptance of VOQUEZNA to be lower than anticipated.
• Risk of encountering coverage, reimbursement, or market access issues.
• Uncertainty regarding the accuracy of patient population and market size estimates.
• Possibility of unexpected adverse side effects or inadequate efficacy of VOQUEZNA.
• Potential delays in clinical trial commencement, enrollment, or data readouts.
• Risk of negative or mixed results from ongoing or future clinical trials.
• Possibility of higher than anticipated operating expenses or cash usage.
• Uncertainty in achieving financial guidance and operating profitability timelines.

Future Outlook

Phathom is updating its full-year 2026 net revenue guidance to $310-$325 million and non-GAAP operating expenses (excluding stock-based compensation) to $235-$245 million. The company expects to achieve operating profitability for the remainder of 2026 and for the full year, excluding stock-based compensation. Gross-to-net discount is expected to be 55-59%, and gross margin around 80%.

Management Comments

• "The second quarter marked an important milestone for Phathom as we delivered strong quarterly revenue growth, achieved operating profitability, excluding stock-based compensation, and continued to build momentum toward realizing the long-term blockbuster potential for VOQUEZNA."
• "Our performance reflects the significant transformation we've made over the past year. We have delivered on the pivot to focus our primary call point on gastroenterologists, substantially reduced our expenses, and nearly doubled quarterly revenue for Q2 of 2026 versus Q2 of 2025."
• "We believe VOQUEZNA has the potential to reach $1 billion in annual revenue through our focus on gastroenterology providers, with an additional $1 billion annual opportunity through expanded engagement in primary care."
• "Phathom is a fundamentally different company than it was a year ago. Our second quarter financial performance demonstrates the continued strengthening of our financial profile as we delivered record quarterly revenue and achieved operating profitability, excluding stock-based compensation, for the first time."
• "Our more moderate revenue guidance still reflects meaningful growth in the second half of 2026."

Industry Context

StockSavvy.ai notes that Phathom Pharmaceuticals' strong Q2 2026 performance, characterized by significant revenue growth and cost reductions, aligns with a broader trend in the biopharmaceutical sector of focusing on commercial execution and pipeline advancement. The company's strategic pivot towards gastroenterologists and the potential for VOQUEZNA to capture substantial market share in GERD and related indications reflect a targeted approach to capitalize on unmet medical needs within the gastrointestinal disease space.

Comparison to Industry Standards

• The 88% year-over-year revenue growth for VOQUEZNA in Q2 2026 is significantly higher than the typical growth rates seen in established pharmaceutical products, indicating strong market penetration and adoption.
• The reduction in operating expenses by 33% year-over-year, while simultaneously increasing revenue, demonstrates efficient operational management, a key benchmark for sustainable growth in the competitive biopharma landscape.
• Achieving operating profitability (excluding stock-based compensation) in Q2 2026, especially for a company commercializing a relatively new product, is a positive indicator of financial health and operational efficiency, often a critical milestone for companies in this sector.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong revenue growth, improved financial performance, and positive pipeline developments. The slight downward revision in full-year guidance may temper immediate enthusiasm.
• Employees: Continued focus on operational efficiency and growth may lead to job security and potential for expansion. Achievement of profitability milestones can boost morale.
• Customers (Patients): Continued availability and potential expansion of VOQUEZNA for GERD and future indications like EoE offer improved treatment options.
• Healthcare Providers: The company's focus on gastroenterologists and potential for new dosing regimens (as-needed) can enhance treatment utility and patient management.

Next Steps

• Initiate Phase 3 clinical trial evaluating as-needed dosing of VOQUEZNA in patients with Non-Erosive GERD (NERD) in Q4 2026.
• Report topline results from the Phase 2 pHalcon-EoE-201 trial in Eosinophilic Esophagitis (EoE) in Q4 2026.
• Discuss potential future development plans in EoE with the FDA, including pediatric evaluation, if Phase 2 results are positive.
• Continue to focus on commercializing VOQUEZNA and achieving long-term blockbuster potential.

Key Dates

Recommendation

The company is showing strong operational improvements and revenue growth, and the pipeline is advancing. However, the continued net loss, a slight downward revision in full-year revenue guidance, and the inherent risks in pharmaceutical development warrant a cautious 'hold' rating until further clarity on profitability and market penetration is achieved.

Keywords

VOQUEZNA, GERD, Eosinophilic Esophagitis, GI diseases, acid suppression, clinical trial, pharmaceutical, revenue growth